Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
Subscribe To Our Newsletter & Stay Updated